Skip to main content

Table 2 BP response rate and BP control rate

From: Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews

Outcome

No.of SRs

No.of original studies

No.of cases/ controls

Follow-up range (weeks)

Estimate (95%CI)

P- value

95%PI

I2(P*)

Egger’s P value

BP response rate

 aliskiren 75 mg vs placebo

2

2

292/291

8

1.41 [1.03–1.94]

0.03

NA

62%(0.11)

NA

 aliskiren150mg vs placebo

2

3

460/451

8

1.42 [1.16–1.75]

0.001

[0.19–10.87]

43%(0.17)

0.008

 aliskiren300mg vs placebo

2

7

1443/1480

8

1.65 [1.46–1.85]

< 0.001

[1.17–2.35]

49%(0.07)

0.167

 aliskiren vs ARBs (low dose)

2

2

479/361

4–8

0.92 [0.81–1.04]

0.16

NA

0%(0.89)

NA

 aliskiren vs ARBs (low to high dose)

2

2

543/570

8–12

0.99 [0.90–1.09]

0.88

NA

0%(0.51)

NA

 aliskiren vs ARBs (high dose)

1

1

175/60

8

1.07 [0.86–1.33]

0.52

NA

NA

NA

 aliskiren vs ACEIs

1

1

414/418

8–26

1.10 [0.99–1.24]

0.09

NA

NA

NA

 aliskiren vs amlodipine

1

2

513/492

8–32

0.77[0.69–0.85]

< 0.00001

NA

0% (0.37)

NA

 aliskiren vs HCTZ

1

1

180/173

8

1.08 [0.92–1.28]

0.34

NA

NA

NA

 aliskiren vs atenolol

1

1

230/230

12

0.84[0.74–0.95]

0.007

NA

NA

NA

BP control rate

 aliskiren 75 mg vs placebo

2

1

177/176

8

1.30 [0.95–1.77]

0.1

NA

NA

NA

 aliskiren150mg vs placebo

2

3

475/666

8

1.51 [1.06–2.16]

0.02

[0.03–76.62]

62%(0.07)

0.084

 aliskiren300mg vs placebo

2

6

1276/1288

8

1.62 [1.10–2.38]

0.01

[0.41–6.36]

90% (< 0.00001)

0.741

 aliskiren vs ARBs (low to high dose)

2

5

919/921

8–12

1.05 [0.89–1.23]

0.57

[0.68–1.62]

37%(0.18)

0.357

 aliskiren vs ARBs (high dose)

1

1

175/60

8

1.01 [0.72–1.43]

0.93

NA

NA

NA

 aliskiren vs ACEIs

1

1

414/418

8–26

1.12 [0.96–1.30]

0.15

NA

NA

NA

 aliskiren vs amlodipine

1

1

201/179

8

0.72 [0.57–0.91]

0.006

NA

NA

NA

 aliskiren vs HCTZ

1

1

180/173

8

1.24 [0.97–1.59]

0.09

NA

NA

NA

 aliskiren vs atenolol

1

1

230/230

12

0.86 [0.68–1.08]

0.18

NA

NA

NA

  1. Notes: Type of metric for comparisons: RR (Risk ratio)
  2. Abbreviations: NA Not Accessible, NR Not Report, SA Systematic review